Companies · NTLA
Intellia Therapeutics
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 5, 2026
Intellia files Q3 2026 10-Q as lonvo-z BLA accepted with Priority Review and March 2027 PDUFA date, positioning first-ever in vivo CRISPR therapy for imminent launch.
Intellia's Q3 2026 10-Q marks a decisive regulatory inflection: the FDA accepted the lonvo-z BLA with Priority Review and a March 10, 2027 PDUFA date, with no advisory committee planned — a signal of FDA confidence in the data package. The company has completed field force deployment and payer engagement in anticipation of a Q1 2027 commercial launch, while simultaneously completing MAGNITUDE-2 enrollment for nex-z in ATTRv-PN and advancing the larger MAGNITUDE trial in ATTR-CM. With $614.8 million in cash and a new $400 million OrbiMed credit facility ($75 million drawn), Intellia is funded at least into 2028, though collaboration revenue declined to $29.9 million for the nine months ended September 30, 2026 versus $44.7 million in the prior-year period.
Tone: bullishRevenue
$67.7M
NTLA 10-K · FY 2025
Revenue FY2024
$57.9M
Founded
2014
Headquarters
Cambridge, MA
Profile
NTLA 10-K Item 1 · Feb 26, 2026Intellia Therapeutics is a clinical-stage biopharmaceutical company developing potentially curative CRISPR-based gene editing therapies for severe diseases. Its two lead product candidates, lonvo-z (NTLA-2002) for hereditary angioedema and nex-z (NTLA-2001) for ATTR amyloidosis, are the first in vivo genome editing programs to enter Phase 3 development. The company plans to commercially launch lonvo-z in the first half of 2027.
Read filing description ↓ Collapse description ↑
Intellia Therapeutics, Inc. is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The Company's mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles ('LNPs'), to develop novel, first-in-class product candidates. This includes the development of lonvoguran ziclumeran ('lonvo-z,' also referred to as NTLA-2002) for the treatment of hereditary angioedema ('HAE') and nexiguran ziclumeran ('nex-z,' also referred to as NTLA-2001) for the treatment of transthyretin ('ATTR') amyloidosis. These lead product candidates are the first in vivo genome editing product candidates into Phase 3 development. These systemically administered CRISPR-based candidates are designed to address diseases with high unmet need with a single intravenous ('IV') infusion that is administered in an outpatient setting. Lonvo-z and nex-z are currently in Phase 3 development, and the Company is preparing for the planned commercial launch of lonvo-z in the first half of 2027. The Company was founded and commenced operations in 2014 and operates as a single reportable segment focused on the development of gene editing-based therapies. All material assets are held in the United States and all collaboration revenue has been generated in the U.S.
Primary products
- lonvoguran ziclumeran (lonvo-z / NTLA-2002)
- nexiguran ziclumeran (nex-z / NTLA-2001)
- CRISPR-based gene editing technologies
- lipid nanoparticles (LNPs)
- oligonucleotides
Business segments
End markets
Geographies
Named customers
Named competitors
Revenue commentary · FY 2025
Collaboration revenue increased by $9.8 million to $67.7 million in 2025 versus $57.9 million in 2024, driven primarily by higher Regeneron cost reimbursements and $9.0 million recognized upon termination of the SparingVision agreement, partially offset by the absence of a $21.0 million AvenCell intra-entity profit recognition that occurred in 2024.
The rest of NTLA is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.